The promising future of ventricular restraint therapy for the management of end-stage heart failure

Complicated pathophysiological syndrome associated with irregular functioning of the heart leading to insufficient blood supply to the organs is linked to congestive heart failure (CHF) which is the leading cause of death in developed countries. Numerous factors can add to heart failure (HF) pathoge...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomedicine & pharmacotherapy 2018-03, Vol.99, p.25-32
Hauptverfasser: Naveed, Muhammad, Mohammad, Imran Shair, Xue, Li, Khan, Sara, Gang, Wang, Cao, Yanfang, Cheng, Yijie, Cui, Xingxing, DingDing, Chen, Feng, Yu, Zhijie, Wang, Xiaohui, Zhou
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 32
container_issue
container_start_page 25
container_title Biomedicine & pharmacotherapy
container_volume 99
creator Naveed, Muhammad
Mohammad, Imran Shair
Xue, Li
Khan, Sara
Gang, Wang
Cao, Yanfang
Cheng, Yijie
Cui, Xingxing
DingDing, Chen
Feng, Yu
Zhijie, Wang
Xiaohui, Zhou
description Complicated pathophysiological syndrome associated with irregular functioning of the heart leading to insufficient blood supply to the organs is linked to congestive heart failure (CHF) which is the leading cause of death in developed countries. Numerous factors can add to heart failure (HF) pathogenesis, including myocardial infarction (MI), genetic factors, coronary artery disease (CAD), ischemia or hypertension. Presently, most of the therapies against CHF cause modest symptom relief but incapable of giving significant recovery for long-term survival outcomes. Unfortunately, there is no effective treatment of HF except cardiac transplantation but genetic variations, tissue mismatch, differences in certain immune response and socioeconomic crisis are some major concern with cardiac transplantation, suggested an alternate bridge to transplant (BTT) or destination therapies (DT). Ventricular restraint therapy (VRT) is a promising, non-transplant surgical treatment wherein the overall goal is to wrap the dilated heart with prosthetic material to mechanically restrain the heart at end-diastole, stop extra remodeling, and thereby ultimately improve patient symptoms, ventricular function and survival. Ventricular restraint devices (VRDs) are developed to treat end-stage HF and BTT, including the CorCap cardiac support device (CSD) (CSD; Acorn Cardiovascular Inc, St Paul, Minn), Paracor HeartNet (Paracor Medical, Sunnyvale, Calif), QVR (Polyzen Inc, Apex, NC) and ASD (ASD, X. Zhou). An overview of 4 restraint devices, with their precise advantages and disadvantages, will be presented. The accessible peer-reviewed literature summarized with an important considerations on the mechanism of restraint therapy and how this acquaintance can be accustomed to optimize and improve its effectiveness.
doi_str_mv 10.1016/j.biopha.2018.01.003
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1989581926</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0753332217354628</els_id><sourcerecordid>1989581926</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-960c9952e50b035114336c2573f3274953434038442be4f2d0b3eec0038da8853</originalsourceid><addsrcrecordid>eNp9kE9r3DAQxUVJaTZpv0EJOuZiZ6SRvNalUELaBgK5pGchy-OsFv_ZSHIg375aNu2xpxHD783Te4x9FVALEM3Nvu7Ccti5WoJoaxA1AH5gG2E0VA3A9oxtYKuxQpTynF2ktAcA3WD7iZ1Lg1IhmA3zTzvih7hMIYX5mQ9rXiPxZeCvNOcY_Dq6yCOlHF2YM887iu7wxoclHt98crN7pqmwRw3NfZVyWfAduZj54MJYzn1mHwc3JvryPi_Z7x93T7e_qofHn_e33x8qj43MlWnAG6MlaegAtRAKsfFSb3FAuVVGo0IF2ColO1KD7KFDIl9it71rW42X7Pp0t-R5WcufbUnlaRzdTMuarDCt0a0wsimoOqE-LilFGuwhhsnFNyvAHuu1e3uq1x7rtSBs8Smyq3eHtZuo_yf622cBvp0AKjlfA0WbfKDZUx8i-Wz7Jfzf4Q8lcYzi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1989581926</pqid></control><display><type>article</type><title>The promising future of ventricular restraint therapy for the management of end-stage heart failure</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Naveed, Muhammad ; Mohammad, Imran Shair ; Xue, Li ; Khan, Sara ; Gang, Wang ; Cao, Yanfang ; Cheng, Yijie ; Cui, Xingxing ; DingDing, Chen ; Feng, Yu ; Zhijie, Wang ; Xiaohui, Zhou</creator><creatorcontrib>Naveed, Muhammad ; Mohammad, Imran Shair ; Xue, Li ; Khan, Sara ; Gang, Wang ; Cao, Yanfang ; Cheng, Yijie ; Cui, Xingxing ; DingDing, Chen ; Feng, Yu ; Zhijie, Wang ; Xiaohui, Zhou</creatorcontrib><description>Complicated pathophysiological syndrome associated with irregular functioning of the heart leading to insufficient blood supply to the organs is linked to congestive heart failure (CHF) which is the leading cause of death in developed countries. Numerous factors can add to heart failure (HF) pathogenesis, including myocardial infarction (MI), genetic factors, coronary artery disease (CAD), ischemia or hypertension. Presently, most of the therapies against CHF cause modest symptom relief but incapable of giving significant recovery for long-term survival outcomes. Unfortunately, there is no effective treatment of HF except cardiac transplantation but genetic variations, tissue mismatch, differences in certain immune response and socioeconomic crisis are some major concern with cardiac transplantation, suggested an alternate bridge to transplant (BTT) or destination therapies (DT). Ventricular restraint therapy (VRT) is a promising, non-transplant surgical treatment wherein the overall goal is to wrap the dilated heart with prosthetic material to mechanically restrain the heart at end-diastole, stop extra remodeling, and thereby ultimately improve patient symptoms, ventricular function and survival. Ventricular restraint devices (VRDs) are developed to treat end-stage HF and BTT, including the CorCap cardiac support device (CSD) (CSD; Acorn Cardiovascular Inc, St Paul, Minn), Paracor HeartNet (Paracor Medical, Sunnyvale, Calif), QVR (Polyzen Inc, Apex, NC) and ASD (ASD, X. Zhou). An overview of 4 restraint devices, with their precise advantages and disadvantages, will be presented. The accessible peer-reviewed literature summarized with an important considerations on the mechanism of restraint therapy and how this acquaintance can be accustomed to optimize and improve its effectiveness.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2018.01.003</identifier><identifier>PMID: 29324309</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>ASD device ; Heart failure ; mVO2 &amp; Ptm ; Remodeling ; Surgery ; Ventricular restraint device (VRD) ; Ventricular restraint therapy (VRT)</subject><ispartof>Biomedicine &amp; pharmacotherapy, 2018-03, Vol.99, p.25-32</ispartof><rights>2018</rights><rights>Copyright © 2018. Published by Elsevier Masson SAS.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-960c9952e50b035114336c2573f3274953434038442be4f2d0b3eec0038da8853</citedby><cites>FETCH-LOGICAL-c362t-960c9952e50b035114336c2573f3274953434038442be4f2d0b3eec0038da8853</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.biopha.2018.01.003$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27911,27912,45982</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29324309$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Naveed, Muhammad</creatorcontrib><creatorcontrib>Mohammad, Imran Shair</creatorcontrib><creatorcontrib>Xue, Li</creatorcontrib><creatorcontrib>Khan, Sara</creatorcontrib><creatorcontrib>Gang, Wang</creatorcontrib><creatorcontrib>Cao, Yanfang</creatorcontrib><creatorcontrib>Cheng, Yijie</creatorcontrib><creatorcontrib>Cui, Xingxing</creatorcontrib><creatorcontrib>DingDing, Chen</creatorcontrib><creatorcontrib>Feng, Yu</creatorcontrib><creatorcontrib>Zhijie, Wang</creatorcontrib><creatorcontrib>Xiaohui, Zhou</creatorcontrib><title>The promising future of ventricular restraint therapy for the management of end-stage heart failure</title><title>Biomedicine &amp; pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>Complicated pathophysiological syndrome associated with irregular functioning of the heart leading to insufficient blood supply to the organs is linked to congestive heart failure (CHF) which is the leading cause of death in developed countries. Numerous factors can add to heart failure (HF) pathogenesis, including myocardial infarction (MI), genetic factors, coronary artery disease (CAD), ischemia or hypertension. Presently, most of the therapies against CHF cause modest symptom relief but incapable of giving significant recovery for long-term survival outcomes. Unfortunately, there is no effective treatment of HF except cardiac transplantation but genetic variations, tissue mismatch, differences in certain immune response and socioeconomic crisis are some major concern with cardiac transplantation, suggested an alternate bridge to transplant (BTT) or destination therapies (DT). Ventricular restraint therapy (VRT) is a promising, non-transplant surgical treatment wherein the overall goal is to wrap the dilated heart with prosthetic material to mechanically restrain the heart at end-diastole, stop extra remodeling, and thereby ultimately improve patient symptoms, ventricular function and survival. Ventricular restraint devices (VRDs) are developed to treat end-stage HF and BTT, including the CorCap cardiac support device (CSD) (CSD; Acorn Cardiovascular Inc, St Paul, Minn), Paracor HeartNet (Paracor Medical, Sunnyvale, Calif), QVR (Polyzen Inc, Apex, NC) and ASD (ASD, X. Zhou). An overview of 4 restraint devices, with their precise advantages and disadvantages, will be presented. The accessible peer-reviewed literature summarized with an important considerations on the mechanism of restraint therapy and how this acquaintance can be accustomed to optimize and improve its effectiveness.</description><subject>ASD device</subject><subject>Heart failure</subject><subject>mVO2 &amp; Ptm</subject><subject>Remodeling</subject><subject>Surgery</subject><subject>Ventricular restraint device (VRD)</subject><subject>Ventricular restraint therapy (VRT)</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kE9r3DAQxUVJaTZpv0EJOuZiZ6SRvNalUELaBgK5pGchy-OsFv_ZSHIg375aNu2xpxHD783Te4x9FVALEM3Nvu7Ccti5WoJoaxA1AH5gG2E0VA3A9oxtYKuxQpTynF2ktAcA3WD7iZ1Lg1IhmA3zTzvih7hMIYX5mQ9rXiPxZeCvNOcY_Dq6yCOlHF2YM887iu7wxoclHt98crN7pqmwRw3NfZVyWfAduZj54MJYzn1mHwc3JvryPi_Z7x93T7e_qofHn_e33x8qj43MlWnAG6MlaegAtRAKsfFSb3FAuVVGo0IF2ColO1KD7KFDIl9it71rW42X7Pp0t-R5WcufbUnlaRzdTMuarDCt0a0wsimoOqE-LilFGuwhhsnFNyvAHuu1e3uq1x7rtSBs8Smyq3eHtZuo_yf622cBvp0AKjlfA0WbfKDZUx8i-Wz7Jfzf4Q8lcYzi</recordid><startdate>20180301</startdate><enddate>20180301</enddate><creator>Naveed, Muhammad</creator><creator>Mohammad, Imran Shair</creator><creator>Xue, Li</creator><creator>Khan, Sara</creator><creator>Gang, Wang</creator><creator>Cao, Yanfang</creator><creator>Cheng, Yijie</creator><creator>Cui, Xingxing</creator><creator>DingDing, Chen</creator><creator>Feng, Yu</creator><creator>Zhijie, Wang</creator><creator>Xiaohui, Zhou</creator><general>Elsevier Masson SAS</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20180301</creationdate><title>The promising future of ventricular restraint therapy for the management of end-stage heart failure</title><author>Naveed, Muhammad ; Mohammad, Imran Shair ; Xue, Li ; Khan, Sara ; Gang, Wang ; Cao, Yanfang ; Cheng, Yijie ; Cui, Xingxing ; DingDing, Chen ; Feng, Yu ; Zhijie, Wang ; Xiaohui, Zhou</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-960c9952e50b035114336c2573f3274953434038442be4f2d0b3eec0038da8853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>ASD device</topic><topic>Heart failure</topic><topic>mVO2 &amp; Ptm</topic><topic>Remodeling</topic><topic>Surgery</topic><topic>Ventricular restraint device (VRD)</topic><topic>Ventricular restraint therapy (VRT)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Naveed, Muhammad</creatorcontrib><creatorcontrib>Mohammad, Imran Shair</creatorcontrib><creatorcontrib>Xue, Li</creatorcontrib><creatorcontrib>Khan, Sara</creatorcontrib><creatorcontrib>Gang, Wang</creatorcontrib><creatorcontrib>Cao, Yanfang</creatorcontrib><creatorcontrib>Cheng, Yijie</creatorcontrib><creatorcontrib>Cui, Xingxing</creatorcontrib><creatorcontrib>DingDing, Chen</creatorcontrib><creatorcontrib>Feng, Yu</creatorcontrib><creatorcontrib>Zhijie, Wang</creatorcontrib><creatorcontrib>Xiaohui, Zhou</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine &amp; pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Naveed, Muhammad</au><au>Mohammad, Imran Shair</au><au>Xue, Li</au><au>Khan, Sara</au><au>Gang, Wang</au><au>Cao, Yanfang</au><au>Cheng, Yijie</au><au>Cui, Xingxing</au><au>DingDing, Chen</au><au>Feng, Yu</au><au>Zhijie, Wang</au><au>Xiaohui, Zhou</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The promising future of ventricular restraint therapy for the management of end-stage heart failure</atitle><jtitle>Biomedicine &amp; pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>2018-03-01</date><risdate>2018</risdate><volume>99</volume><spage>25</spage><epage>32</epage><pages>25-32</pages><issn>0753-3322</issn><eissn>1950-6007</eissn><abstract>Complicated pathophysiological syndrome associated with irregular functioning of the heart leading to insufficient blood supply to the organs is linked to congestive heart failure (CHF) which is the leading cause of death in developed countries. Numerous factors can add to heart failure (HF) pathogenesis, including myocardial infarction (MI), genetic factors, coronary artery disease (CAD), ischemia or hypertension. Presently, most of the therapies against CHF cause modest symptom relief but incapable of giving significant recovery for long-term survival outcomes. Unfortunately, there is no effective treatment of HF except cardiac transplantation but genetic variations, tissue mismatch, differences in certain immune response and socioeconomic crisis are some major concern with cardiac transplantation, suggested an alternate bridge to transplant (BTT) or destination therapies (DT). Ventricular restraint therapy (VRT) is a promising, non-transplant surgical treatment wherein the overall goal is to wrap the dilated heart with prosthetic material to mechanically restrain the heart at end-diastole, stop extra remodeling, and thereby ultimately improve patient symptoms, ventricular function and survival. Ventricular restraint devices (VRDs) are developed to treat end-stage HF and BTT, including the CorCap cardiac support device (CSD) (CSD; Acorn Cardiovascular Inc, St Paul, Minn), Paracor HeartNet (Paracor Medical, Sunnyvale, Calif), QVR (Polyzen Inc, Apex, NC) and ASD (ASD, X. Zhou). An overview of 4 restraint devices, with their precise advantages and disadvantages, will be presented. The accessible peer-reviewed literature summarized with an important considerations on the mechanism of restraint therapy and how this acquaintance can be accustomed to optimize and improve its effectiveness.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>29324309</pmid><doi>10.1016/j.biopha.2018.01.003</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0753-3322
ispartof Biomedicine & pharmacotherapy, 2018-03, Vol.99, p.25-32
issn 0753-3322
1950-6007
language eng
recordid cdi_proquest_miscellaneous_1989581926
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ScienceDirect Journals (5 years ago - present)
subjects ASD device
Heart failure
mVO2 & Ptm
Remodeling
Surgery
Ventricular restraint device (VRD)
Ventricular restraint therapy (VRT)
title The promising future of ventricular restraint therapy for the management of end-stage heart failure
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T20%3A17%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20promising%20future%20of%20ventricular%20restraint%20therapy%20for%20the%20management%20of%20end-stage%20heart%20failure&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Naveed,%20Muhammad&rft.date=2018-03-01&rft.volume=99&rft.spage=25&rft.epage=32&rft.pages=25-32&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2018.01.003&rft_dat=%3Cproquest_cross%3E1989581926%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1989581926&rft_id=info:pmid/29324309&rft_els_id=S0753332217354628&rfr_iscdi=true